{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:47:46Z","timestamp":1795034866632,"version":"4.10.2"},"reference-count":100,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,4,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The morbidity and mortality of patients with the chronic Philadelphia-negative myeloproliferative neoplasms (MPNs), essential thrombocythemia, polycythemia vera, and primary myelofibrosis are mainly caused by cardiovascular diseases, thrombohemorrhagic complications, and bone marrow failure because of myelofibrosis and leukemic transformation. In the general population, chronic inflammation is considered of major importance for the development of atherosclerosis and cancer. MPNs are characterized by a state of chronic inflammation, which is proposed to be the common denominator for the development of \u201cpremature atherosclerosis,\u201d clonal evolution, and second cancer in patients with MPNs. Chronic inflammation may both initiate clonal evolution and catalyze its expansion from early disease stage to the myelofibrotic burnt-out phase. Furthermore, chronic inflammation may also add to the severity of cardiovascular disease burden by accelerating the development of atherosclerosis, which is well described and recognized in other chronic inflammatory diseases. A link between chronic inflammation, atherosclerosis, and second cancer in MPNs favors early intervention at the time of diagnosis (statins and interferon-\u03b12), the aims being to dampen chronic inflammation and clonal evolution and thereby also diminish concurrent disease-mediated chronic inflammation and its consequences (accelerated atherosclerosis and second cancer).<\/jats:p>","DOI":"10.1182\/blood-2011-11-394775","type":"journal-article","created":{"date-parts":[[2012,2,8]],"date-time":"2012-02-08T02:20:40Z","timestamp":1328667640000},"page":"3219-3225","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":303,"title":["Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?"],"prefix":"10.1182","volume":"119","author":[{"given":"Hans Carl","family":"Hasselbalch","sequence":"first","affiliation":[{"name":"Department of Hematology, Roskilde Hospital, University of Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"23","key":"2019111808035985700_B1","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"Mechanisms of disease: the myeloproliferative disorders.","volume":"355","author":"Campbell","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111808035985700_B2","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH, IKZF1.","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"2019111808035985700_B3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3324\/haematol.2010.031070","article-title":"Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.","volume":"96","author":"Barbui","year":"2011","journal-title":"Haematologica"},{"issue":"4","key":"2019111808035985700_B4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ajh.2830340411","article-title":"Idiopathic myelofibrosis: a clinical study of 80 patients.","volume":"34","author":"Hasselbalch","year":"1990","journal-title":"Am J Hematol"},{"issue":"7","key":"2019111808035985700_B5","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2009.020412","article-title":"Autoimmunity and the risk of myeloproliferative neoplasms.","volume":"95","author":"Kristinsson","year":"2010","journal-title":"Haematologica"},{"key":"2019111808035985700_B6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis: an inflammatory disease.","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111808035985700_B7","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ni.2001","article-title":"The immune system in atherosclerosis.","volume":"12","author":"Hansson","year":"2011","journal-title":"Nat Immunol"},{"issue":"2","key":"2019111808035985700_B8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/ncprheum0092","article-title":"Mechanisms of disease: atherosclerosis in autoimmune diseases.","volume":"2","author":"Sherer","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"11","key":"2019111808035985700_B9","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/art.25009","article-title":"Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis.","volume":"61","author":"Rho","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2019111808035985700_B10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2133.2009.09281.x","article-title":"More than skin deep: atherosclerosis as a systemic manifestation of psoriasis.","volume":"161","author":"Alexandroff","year":"2009","journal-title":"Br J Dermatol"},{"issue":"25","key":"2019111808035985700_B11","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMp038168","article-title":"Systemic lupus erythematosus and accelerated atherosclerosis.","volume":"349","author":"Hahn","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111808035985700_B12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.it.2003.10.013","article-title":"Inflammation: the link between insulin resistance, obesity and diabetes.","volume":"25","author":"Dandona","year":"2004","journal-title":"Trends Immunol"},{"issue":"9","key":"2019111808035985700_B13","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1210\/jc.2008-2534","article-title":"Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications.","volume":"94","author":"Goldberg","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"15","key":"2019111808035985700_B14","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMoa022157","article-title":"An association between atherosclerosis and venous thrombosis.","volume":"348","author":"Prandoni","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111808035985700_B15","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-phase proteins and other systemic responses to inflammation.","volume":"340","author":"Gabay","year":"1999","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111808035985700_B16","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/j.atherosclerosis.2007.04.053","article-title":"C-reactive protein and atherogenesis: from fatty streak to clinical event.","volume":"195","author":"Bisoendial","year":"2007","journal-title":"Atherosclerosis"},{"issue":"17","key":"2019111808035985700_B17","first-page":"2135","article-title":"Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis.","volume":"113","author":"Verma","year":"2006","journal-title":"Circulation"},{"issue":"9709","key":"2019111808035985700_B18","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.","volume":"375","author":"Emerging Risk Factors Collaboration","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"2019111808035985700_B19","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMra052723","article-title":"The many roles of chemokines and chemokine receptors in inflammation.","volume":"354","author":"Charo","year":"2006","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111808035985700_B20","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis.","volume":"357","author":"Dav\u00ec","year":"2007","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111808035985700_B21","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1161\/ATVBAHA.110.207480","article-title":"Platelet-leukocyte interactions in cardiovascular disease and beyond.","volume":"30","author":"Totani","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"16","key":"2019111808035985700_B22","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJM200010193431602","article-title":"Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease.","volume":"343","author":"Lindahl","year":"2000","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111808035985700_B23","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1161\/01.CIR.102.6.636","article-title":"PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans.","volume":"102","author":"Peri","year":"2000","journal-title":"Circulation"},{"issue":"3","key":"2019111808035985700_B24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","article-title":"Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.","volume":"128","author":"Elliott","year":"2005","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111808035985700_B25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3324\/haematol.2010.038299","article-title":"Pathophysiology of thrombosis in myeloproliferative neoplasms.","volume":"96","author":"Landolfi","year":"2011","journal-title":"Haematologica"},{"issue":"2","key":"2019111808035985700_B26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2006.06430.x","article-title":"The haematocrit and platelet target in polycythemia vera.","volume":"136","author":"Di Nisio","year":"2007","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111808035985700_B27","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.exphem.2007.01.053","article-title":"V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules.","volume":"35","author":"Falanga","year":"2007","journal-title":"Exp Hematol"},{"issue":"4","key":"2019111808035985700_B28","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2009-02-206797","article-title":"Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?","volume":"114","author":"Barbui","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2019111808035985700_B29","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111808035985700_B30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3324\/haematol.2009.011866","article-title":"Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2).","volume":"95","author":"Quist-Paulsen","year":"2010","journal-title":"Haematologica"},{"issue":"8","key":"2019111808035985700_B31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1161\/CIRCULATIONAHA.108.806547","article-title":"Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis.","volume":"120","author":"Norata","year":"2009","journal-title":"Circulation"},{"issue":"12","key":"2019111808035985700_B32","first-page":"2447","article-title":"Role of insulin resistance in increased frequency of atherosclerosis detected by carotid ultrasonography in rheumatoid arthritis.","volume":"33","author":"Pamuk","year":"2006","journal-title":"J Rheumatol"},{"issue":"2","key":"2019111808035985700_B33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3132\/dvdr.2007.031","article-title":"Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis.","volume":"4","author":"La Montagna","year":"2007","journal-title":"Diab Vasc Dis Res"},{"issue":"11","key":"2019111808035985700_B34","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.amjcard.2005.07.068","article-title":"Status of endothelial dependent vasodilation in patients with hyperuricemia.","volume":"96","author":"Kato","year":"2005","journal-title":"Am J Cardiol"},{"issue":"7","key":"2019111808035985700_B35","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/ajh.2011.55","article-title":"Relationships among hyperuricemia, metabolic syndrome, and endothelial function.","volume":"24","author":"Tomiyama","year":"2011","journal-title":"Am J Hypertens"},{"issue":"8","key":"2019111808035985700_B36","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","article-title":"Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.","volume":"5","author":"Goicoechea","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"2019111808035985700_B37","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/ki.2011.147","article-title":"Myeloproliferative neoplasms cause glomerulopathy.","volume":"80","author":"Said","year":"2011","journal-title":"Kidney Int"},{"issue":"6917","key":"2019111808035985700_B38","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer.","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"issue":"11","key":"2019111808035985700_B39","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1002\/ijc.23173","article-title":"Inflammation and cancer: an ancient link with novel potentials.","volume":"121","author":"Hussain","year":"2007","journal-title":"Int J Cancer"},{"issue":"3","key":"2019111808035985700_B40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/07853890903405753","article-title":"Molecular pathways and targets in cancer-related inflammation.","volume":"42","author":"Mantovani","year":"2010","journal-title":"Ann Med"},{"issue":"9255","key":"2019111808035985700_B41","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"issue":"10","key":"2019111808035985700_B42","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nri1703","article-title":"NF-kappaB: linking inflammation and immunity to cancer development and progression.","volume":"5","author":"Karin","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2019111808035985700_B43","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1080\/10428190902780677","article-title":"Autoimmunity and hematologic malignancies: associations and mechanisms.","volume":"50","author":"Martin","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2019111808035985700_B44","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1365-2796.2008.02029.x","article-title":"Autoimmune and inflammatory disorders and risk of malignant lymphomas: an update.","volume":"264","author":"Smedby","year":"2008","journal-title":"J Intern Med"},{"issue":"4","key":"2019111808035985700_B45","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.autrev.2010.11.001","article-title":"Excess of autoimmune and chronic inflammatory disorders in patients with lymphoma compared with all cancer patients: a cancer registry-based analysis in the south of the Netherlands.","volume":"10","author":"van de Schans","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"5","key":"2019111808035985700_B46","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.bjc.6604935","article-title":"Risks of myeloid malignancies in patients with autoimmune conditions.","volume":"100","author":"Anderson","year":"2009","journal-title":"Br J Cancer"},{"issue":"21","key":"2019111808035985700_B47","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1200\/JCO.2011.34.8540","article-title":"Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes.","volume":"29","author":"Kristinsson","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111808035985700_B48","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2141.2005.05674.x","article-title":"Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases.","volume":"130","author":"Panteli","year":"2005","journal-title":"Br J Haematol"},{"issue":"10","key":"2019111808035985700_B49","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111808035985700_B50","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1600-0609.2011.01618.x","article-title":"Whole blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis.","volume":"87","author":"Skov","year":"2011","journal-title":"Eur J Haematol"},{"key":"2019111808035985700_B51","first-page":"4115","article-title":"Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis [abstract].","volume":"116","author":"Skov","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"7","key":"2019111808035985700_B52","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1158\/1055-9965.EPI-09-0353","article-title":"Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.","volume":"18","author":"Vannucchi","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"25","key":"2019111808035985700_B53","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","article-title":"Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study.","volume":"118","author":"Frederiksen","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2019111808035985700_B54","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1365-2362.2004.01417.x","article-title":"Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts.","volume":"34","author":"Voulgarelis","year":"2004","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"2019111808035985700_B55","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2141.1983.tb02048.x","article-title":"Immune disorders in agnogenic myeloid metaplasia: relations to myelofibrosis.","volume":"53","author":"Rondeau","year":"1983","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111808035985700_B56","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-0609.1985.tb02252.x","article-title":"Circulating immune complexes in myelofibrosis.","volume":"34","author":"Hasselbalch","year":"1985","journal-title":"Scand J Haematol"},{"issue":"3","key":"2019111808035985700_B57","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/10428190310001597982","article-title":"Autoimmune myelofibrosis: report of three cases and review of the literature.","volume":"45","author":"Rizzi","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2019111808035985700_B58","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.leukres.2010.05.010","article-title":"Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis?","volume":"34","author":"Barosi","year":"2010","journal-title":"Leuk Res"},{"issue":"11","key":"2019111808035985700_B59","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3324\/haematol.2011.055392","article-title":"The JAK2 46\/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defence against infection?","volume":"96","author":"Hermouet","year":"2011","journal-title":"Haematologica"},{"issue":"3","key":"2019111808035985700_B60","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3324\/haematol.2010.033191","article-title":"The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.","volume":"96","author":"Nielsen","year":"2011","journal-title":"Haematologica"},{"issue":"12","key":"2019111808035985700_B61","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1182\/blood-2005-10-4169","article-title":"Role of transforming growth factor-beta in hematologic malignancies.","volume":"107","author":"Dong","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2019111808035985700_B62","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/14712598.7.4.449","article-title":"Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.","volume":"7","author":"Johnson","year":"2007","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"2019111808035985700_B63","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.it.2010.04.002","article-title":"TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression.","volume":"31","author":"Yang","year":"2010","journal-title":"Trends Immunol"},{"issue":"24","key":"2019111808035985700_B64","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"Tumor necrosis factor-alpha facilitates clonal expansion of JAK2V617F-positive cells in myeloproliferative neoplasms.","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2019111808035985700_B65","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/ng.175","article-title":"Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease.","volume":"40","author":"Barrett","year":"2008","journal-title":"Nat Genet"},{"issue":"1","key":"2019111808035985700_B66","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.mrfmmm.2010.01.017","article-title":"Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population.","volume":"690","author":"Ferguson","year":"2010","journal-title":"Mutat Res"},{"issue":"5","key":"2019111808035985700_B67","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1182\/blood-2007-06-095703","article-title":"Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders.","volume":"111","author":"Pardanani","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111808035985700_B68","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.342","article-title":"A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.","volume":"41","author":"Kilpivaara","year":"2009","journal-title":"Nat Genet"},{"issue":"4","key":"2019111808035985700_B69","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.","volume":"41","author":"Jones","year":"2009","journal-title":"Nat Genet"},{"issue":"4","key":"2019111808035985700_B70","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ng.341","article-title":"A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.","volume":"41","author":"Olcaydu","year":"2009","journal-title":"Nat Genet"},{"issue":"1","key":"2019111808035985700_B71","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/leu.2009.225","article-title":"JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46\/1 haplotype is associated with inferior survival.","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"22","key":"2019111808035985700_B72","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1182\/blood-2009-08-236448","article-title":"The JAK2 46\/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms.","volume":"115","author":"Jones","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111808035985700_B73","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood-2008-01-134114","article-title":"JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders.","volume":"112","author":"Plo","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019111808035985700_B74","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer.","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"10","key":"2019111808035985700_B75","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nri910","article-title":"NF-kappaB regulation in the immune system.","volume":"2","author":"Li","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"5288","key":"2019111808035985700_B76","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1126\/science.274.5288.782","article-title":"An essential role for NF-kappaB in preventing TNF-alpha induced cell death.","volume":"274","author":"Beg","year":"1996","journal-title":"Science"},{"issue":"7007","key":"2019111808035985700_B77","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature02924","article-title":"NF-kappaB functions as a tumour promoter in inflammation-associated cancer.","volume":"431","author":"Pikarsky","year":"2004","journal-title":"Nature"},{"issue":"2","key":"2019111808035985700_B78","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1359-6101(01)00020-X","article-title":"Tumor necrosis factor or tumor promoting factor?","volume":"13","author":"Balkwill","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"issue":"9","key":"2019111808035985700_B79","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/eji.201141727","article-title":"Monocytes link atherosclerosis and cancer.","volume":"41","author":"Pittet","year":"2011","journal-title":"Eur J Immunol"},{"issue":"11","key":"2019111808035985700_B80","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.leukres.2006.12.025","article-title":"Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis.","volume":"31","author":"Elliott","year":"2007","journal-title":"Leuk Res"},{"issue":"1","key":"2019111808035985700_B81","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis.","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"issue":"9","key":"2019111808035985700_B82","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1002\/eji.201141894","article-title":"Cancer-promoting tumor-associated macrophages: new vistas and open questions.","volume":"41","author":"Mantovani","year":"2011","journal-title":"Eur J Immunol"},{"issue":"10","key":"2019111808035985700_B83","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111808035985700_B84","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.1073\/pnas.0401060101","article-title":"Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis.","volume":"101","author":"Monaco","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"2019111808035985700_B85","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2010.03.013","article-title":"Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity.","volume":"55","author":"Venuraju","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2019111808035985700_B86","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/ATVBAHA.109.199661","article-title":"Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular diseases and mortality.","volume":"30","author":"Lieb","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"2019111808035985700_B87","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.4049\/jimmunol.153.6.2819","article-title":"Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines: potential role for interleukin-1 and TGF-beta.","volume":"153","author":"Rameshwar","year":"1994","journal-title":"J Immunol"},{"issue":"2","key":"2019111808035985700_B88","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/(SICI)1096-8652(199810)59:2<133::AID-AJH6>3.0.CO;2-Z","article-title":"Systemic transforming growth factor-beta in patients with bone marrow fibrosis: pathophysiological implications.","volume":"59","author":"Rameshwar","year":"1998","journal-title":"Am J Hematol"},{"issue":"8","key":"2019111808035985700_B89","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1158\/0008-5472.CAN-04-2339","article-title":"Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression.","volume":"65","author":"Komura","year":"2005","journal-title":"Cancer Res"},{"issue":"3","key":"2019111808035985700_B90","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1365-2141.2010.08249.x","article-title":"JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation.","volume":"150","author":"Oku","year":"2010","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111808035985700_B91","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3.","volume":"9","author":"Yu","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2019111808035985700_B92","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/01.ATV.0000156877.94472.a5","article-title":"Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene?","volume":"25","author":"Coller","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"23","key":"2019111808035985700_B93","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111808035985700_B94","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111808035985700_B95","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","article-title":"A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms.","volume":"150","author":"Rambaldi","year":"2010","journal-title":"Br J Haematol"},{"key":"2019111808035985700_B96","article-title":"A Phase II study of vorinostat (MK-0683) in patients with polycythaemia vera essential thrombocythaemia [abstract].","volume-title":"Haematologica","author":"Andersen","year":"2011"},{"issue":"10","key":"2019111808035985700_B97","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.leukres.2005.12.018","article-title":"Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?","volume":"30","author":"Hasselbalch","year":"2006","journal-title":"Leuk Res"},{"key":"2019111808035985700_B98","article-title":"A mechanistic rationale for the use of statins to enhance JAK2 inhibitor therapy in MPNs [abstract].","volume":"118","author":"Griner","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"1","key":"2019111808035985700_B99","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.leukres.2008.06.002","article-title":"Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer: time to change our therapeutic attitude with early upfront treatment?","volume":"33","author":"Hasselbalch","year":"2009","journal-title":"Leuk Res"},{"issue":"6","key":"2019111808035985700_B100","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1586\/ehm.11.63","article-title":"A new era for interferon-alpha2 in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.","volume":"4","author":"Hasselbalch","year":"2011","journal-title":"Expert Rev Hematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/14\/3219\/1350617\/zh801412003219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/14\/3219\/1350617\/zh801412003219.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T01:14:24Z","timestamp":1713489264000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/14\/3219\/29545\/Perspectives-on-chronic-inflammation-in-essential"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,5]]},"references-count":100,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2012,4,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-11-394775","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,5]]}}}